165 results about "Vincristine" patented technology

This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.

The invention relates to an action of ferulic acid on enhancing the drug effect of some medicaments and a purpose thereof, wherein the medicaments mainly comprise alkaloid medicaments including matrine, kushenin, sophocarpine, hyoscyamine, narceine, hanfangchin A, jamaicin, morphine, codeine, evodiamine, strychnine, catharanthine, vincristine, taxol, verticine, peimine, peiminine, ephedrine, pseudoephedrine, wilfordine, triptolide, tripdiolide and the like, and flavonoid medicaments including puerarin, ginsenoside, ginsengenin, mangiferin, scutelloside, alkannin, meletin, rutin, hesperidin, daidzin, soybean isoflavone, daidzein, carthamin, catechin and the like. The ferulic acid and the medicaments can form a compound or a medicament compound, or the ferulic acid and the medicaments can generate a chemical reaction (including salification, esterification, amidation, ketonization, etherification and the like), and/or the ferulic acid and the medicaments can generate a synergistic effect and an additive effect.

The present invention discloses one kind of folic acid acceptor targeting liposome as medicine carrier and its preparation process and application. The liposome has components including synthetic phospholipid, cholesterol, folic acid acceptor targeting anchor point and polyglycol hydrating anchor point. The present invention has relatively simple preparation process, and can prepare liposome of size smaller than 200 nm in large scale and prepare freeze dried powder of weak alkali medicine, including leurocristine, etc. carried on the liposome with greatly raised use convenience and stability. The medicine is re-constructed with bacteria-free water or brine before use, and the medicine leakage rate is lower than 10 %.

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.

The invention provides intravenous nanomicelle agents of vinca alkaloids antitumor drug, it contains an effective dose for treating of vinca alkaloids antitumor drug (vinblastine and vincristine or vindesine), macrogol derivatization phospholipid, and the pharmaceutical acceptable adjuvants. Its preparation is to pack the drug in the formative nanomicelle agents, prepare and make the intravenous nanomicelle agents of vinca alkaloids antitumor drug. Vinca alkaloids antitumor drug and macrogol derivatization phospholipid form into a very uniform size nanomicelle. In micelles, polyethylene glycol molecule and hydrophobic core for drug packing form a hydrophilicitious inhibitory coating, avoid the drugs contact with the protein such as enzymes in the blood and identified and phagocytized by the endothelial system in vivo, phagocytosis, the cycle time of micellar in vivo is extended. In addition, the micellar drug also increases the storage stability and the effect on the tumor of the drug and reduces drug toxicity.

The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed.

This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.

The invention relates to the technical field of medicaments, which is a novel cyclic octapeptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic octapeptide compound is shown as a formula (I), wherein a group R1 is expressed as a formula (II), R2 represents CH (CH3)2or CHCH3(CH2CH3), R3 represents CH2CH (CH3)2, R4 represents CHCH3(CH2CH3)or CHOH (CH3), and R5 represents CHCH3(CH2CH3)or CH2CH (CH3)2. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of a mouse P388 is only 7.8 mu g/ml and is superior to a positive control medicament vincristine, so the cyclic octapeptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.

The invention discloses a quinine drug-vincristine drug co-carried liposome and a preparation method thereof. The liposome comprises drugs, a phospholipid, a cholesterol compound and an aqueous medium, wherein the mass ratio of the drugs, the phospholipid and the cholesterol compound is 1:(2-100):(1-35), and the drugs comprise a quinine drug and a vincristine drug. With utilization of the synergistic effect of the quinine drug and the vincristine drug, the quinine drug-vincristine drug co-carried liposome has the characteristics of inhibition of multidrug resistance and reduction of medicating toxicity. The preparation method of the co-carried liposome is simple in preparation process, mild in conditions, fewer control parameters, beneficial for reducing the production cost, and easy to industrially produce.

A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine.

The invention relates to the technical field of medicaments, which is a novel cyclic heptapeptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic heptapeptide compound is shown as the right formula. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of SPC-A-1 cells is only 31.4 mu g/ml and is superior to a positive control medicament vincristine, so the cyclic heptapeptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.

The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.

The invention discloses application of cyclic dinucleotide cGAMP to prevention and treatment of tumors through drug combination, belonging to the technical field of biological medicine. The invention also discloses a plurality of drug compositions for prevention and treatment of tumors. The drug compositions for prevention and treatment of tumors are composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin. Results of in-vivo research show that the drug compositions composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin have obviously improved curative effect and obviously decreased toxicity.

The invention relates to the technical field of medicaments, which is a novel cyclic peptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic peptide compound is shown as the right formula. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of BEL-7402 cells is only 29.7 mu g/ml and is obviously superior to a positive control medicament vincristine, so the cyclic peptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.

The invention relates to indole alkaloid formalardeemin shown in a chemical structural formula ((-)-5-N-formalardeemin), pharmaceutically acceptable salts of the same, and application of the indole alkaloid formalardeemin serving as an anti-tumor medicament in curing malignant tumors of human beings. The indole alkaloid formalardeemin serving as an anti-tumor medicament can not only inhibit the growth of malignant tumors directly, but also can be used as a chemosensitizer when used together with other anti-tumor medicaments such as doxorubicine, vincristine and the like to achieve the effect of effectively killing tumor cells by reversing the multi-drug resistance of the tumor cells. More significantly, compared with the indole alkaloid formalardeemin serving as a tumor cell growth inhibitor directly, the indole alkaloid formalardeemin serving as the chemosensitizer has a better effect, so the indole alkaloid formalardeemin has important clinical application prospect.

The invention relates to a vincristine-reversion agent compound nano particle, a preparation thereof and applications, belonging to the medicine field. A first technical problem to be solved by the invention is: overcoming the phenomena of multidrug resistance MDR of various tumor cells to the vincristine, namely, the vincristine and the reversion agent are wrapped and carried in a PLGA in a compound way, for preparing the nano particles. With the purposes of obtaining the smaller-diameter nano particles and reducing the vestigital of the surface active agent, F68 and TPGS are adopted as the surface active agent; compared with PVA, the TPGS and the F68 can obviously increase the mortality of drug-resistant breast cancer cells (p is smaller than 0.05); and the tumor-inhibition rate of the TPGS is obviously higher than that of the F68.

The invention relates to a vincristine nano targeting slow-release long-circulation liposome and a preparation method thereof. The uniform particle size of the liposome is in the range of 50-200 nm, and polyethylene glycol and folic acid are rich on the surfaces of the liposome particles. The ratio in parts by mass of raw materials is that folate-conjugated octadecyl-quaternized lysine modified chitosan (FA-OQLCS): PEGlated octadecyl-quaternized lysine modified chitosan (PEG-OQLCS): vincristine=1: (1-2): (0.5-1); the ratio of the total amount of FA-OQLCS and PEG-OQLCS to cholesterol=(4-2):1; the liposome is prepared by a reverse-phase evaporation method or thin-film dispersion method; the entire preparation method is simple and rapid, the preparation period is short, and the drug loading rate of the prepared polymer liposome is up to 9.7%; and the surface polyethylene glycol modification enables the polymer liposome not to be easily caught by a human reticulo-endothelial system and prolongs the circulation time of the polymer liposome, and the folate modification contributes to the tumor targeting property of the polymer liposome.

This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.

The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.

The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein the agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265,Rotenone, Idarubicin, Dequalintum chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence- associated disease or disorder, and methods relating thereto.